Lv2
140 积分 2023-05-04 加入
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
1小时前
已完结
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted
9天前
已完结
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study
27天前
已完结
Current Status on Management of Primary Plasma Cell Leukemia
27天前
已完结
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy
28天前
已完结
Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab
28天前
已完结
Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab
28天前
已完结
T(11;14) with multiple myeloma: Standard risk survival but slow and poor response
29天前
已完结
Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab
1个月前
已完结
T(11;14) with multiple myeloma: Standard risk survival but slow and poor response
1个月前
已完结
皖公网安备34019202002308
